Acrivon Therapeutics Files 8-K

Ticker: ACRV · Form: 8-K · Filed: Sep 16, 2024 · CIK: 1781174

Acrivon Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAcrivon Therapeutics, Inc. (ACRV)
Form Type8-K
Filed DateSep 16, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.001, $220.4 million
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k, disclosure

Related Tickers: ACRN

TL;DR

ACRN filed an 8-K, check for updates.

AI Summary

On September 14, 2024, Acrivon Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific material events or financial figures beyond the filing date and company information were detailed in the provided text.

Why It Matters

This 8-K filing indicates Acrivon Therapeutics is providing updates and disclosures to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The provided text is a standard 8-K filing header and does not contain specific material events or financial disclosures that would indicate a change in risk.

Key Players & Entities

  • Acrivon Therapeutics, Inc. (company) — Registrant
  • 0001781174 (company) — Central Index Key
  • 2834 (company) — Standard Industrial Classification (Pharmaceutical Preparations)
  • 825125532 (company) — IRS Number
  • 001-41551 (company) — SEC File Number
  • September 14, 2024 (date) — Date of earliest event reported
  • 480 Arsenal Way, Suite 100 (location) — Principal Executive Offices
  • Watertown, Massachusetts (location) — Principal Executive Offices
  • 02472 (location) — Principal Executive Offices Zip Code
  • 617-207-8979 (phone_number) — Registrant's Telephone Number

FAQ

What is the primary purpose of this 8-K filing?

The filing is a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, covering Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported is September 14, 2024.

What is Acrivon Therapeutics, Inc.'s principal executive office address?

The principal executive offices are located at 480 Arsenal Way, Suite 100, Watertown, Massachusetts, 02472.

What is Acrivon Therapeutics, Inc.'s SEC File Number?

Acrivon Therapeutics, Inc.'s SEC File Number is 001-41551.

What is the Standard Industrial Classification code for Acrivon Therapeutics, Inc.?

The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 1,037 words · 4 min read · ~3 pages · Grade level 12.7 · Accepted 2024-09-16 06:43:01

Key Financial Figures

  • $0.001 — nge on which registered Common Stock, $0.001 par value ACRV The Nasdaq Stock Mar
  • $220.4 million — sh, cash equivalents and investments of $220.4 million as of June 30, 2024, will be sufficient

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits: Exhibit Number Exhibit Description 99.1 Press Release, dated September 14, 2024 99.2 Acrivon Therapeutics, Inc. Presentation, dated September 14, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Acrivon Therapeutics, Inc. Dated: September 16, 2024 By: /s/ Peter Blume-Jensen Name: Peter Blume-Jensen, M.D., Ph.D. Title: Chief Executive Officer and President

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.